The report highlights Daiichi Sankyo's commitment to sustainability and its progress in environmental, social, and governance (ESG) initiatives. The company achieved a 49.6% reduction in global CO2 emissions and transitioned to renewable energy for electricity at its head office and all of its plants and research centers in Japan. Daiichi Sankyo also achieved a 78.1% renewable electricity utilization rate and was selected as 'A List' Companies in CDP Climate Change for three consecutive years. In addition, Daiichi Sankyo has been recognized for its leadership in transparency and performance in corporate sustainability related to climate change by CDP. The company is also promoting initiatives to address human rights issues and has established a human rights due diligence system to prevent negative impacts on human rights. Daiichi Sankyo is committed to combating the threat of counterfeit pharmaceuticals and continues to implement serialization technologies and other anti-counterfeit measures. The report also highlights the company's commitment to inclusion and diversity and its efforts to create a workplace environment that values diverse perspectives and encourages employee engagement. Daiichi Sankyo's commitment to research and development is also highlighted, with the company making significant investments in the development of new medicines and vaccines.
